Organization
Australasian Gastro-Intestinal Trials Group
8 clinical trials
2 abstracts
Abstract
AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).Org: NHMRC Clinical Trial Centre, Shoalhaven District Memorial Hospital, Flinders Medical Centre, Australasian Gastro-Intestinal Trials Group, Sunshine Hospital,
Clinical trial
NEO-adjuvant Chemo-Immunotherapy in Pancreatic CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1/LSTA1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
PALEO: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer ComplicationsStatus: Recruiting, Estimated PCD: 2027-07-31
Abstract
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.Org: St. John of God Hospital Subiaco, Queen Elizabeth Hospital, University of Adelaide, Woodville, St. George Hospital,